Your browser doesn't support javascript.
loading
Immunological Landscape of HER-2 Positive Breast Cancer.
Moragon, Santiago; Hernando, Cristina; Martinez-Martinez, Maria Teresa; Tapia, Marta; Ortega-Morillo, Belen; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel.
Affiliation
  • Moragon S; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain.
  • Hernando C; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain.
  • Martinez-Martinez MT; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain.
  • Tapia M; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain.
  • Ortega-Morillo B; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain.
  • Lluch A; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain.
  • Bermejo B; Instituto de Salud Carlos III, CIBERONC (Centro De Investigacion Biomedica En Red De Cancer), 28220 Madrid, Spain.
  • Cejalvo JM; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain.
Cancers (Basel) ; 14(13)2022 Jun 28.
Article in En | MEDLINE | ID: mdl-35804943
ABSTRACT
Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved survival in this population, yet a substantial percentage may relapse, creating a need within the scientific community to uncover resistance mechanisms and determine how to overcome them. This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Systematic_reviews Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Spain
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Systematic_reviews Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Spain